Clinical Trials Logo

Anhedonia clinical trials

View clinical trials related to Anhedonia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05849675 Completed - Cognitive Function Clinical Trials

Pitolisant Effects on Affect and Cognition Exploratory Study (PEACE Study)

PEACE
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to investigate the effects of selective histamine 3 antagonist pitolisant on brain function and cognition in healthy individuals. The main questions it aims to answer are: 1. Does pitolisant alter functional activity in brain regions linked to reward and cognitive processing during rest or cognitive task performance? 2. Does pitolisant alter cognitive ability across a range of psychological domains, including working memory, executive functioning and emotional processing? Participants will undertake fMRI scanning in addition to a battery of tasks designed to measure cognitive and emotional processing after taking a single dose of pitolisant or placebo. Researchers will compare differences in functional activity, cognition and emotional processing across the pitolisant and placebo groups.

NCT ID: NCT05383248 Completed - Depression Clinical Trials

Computational Cognitive Training To Boost Reward Responsiveness In Anhedonic Patients

Start date: September 14, 2022
Phase: N/A
Study type: Interventional

Anhedonia, i.e., reduced positive mood and decreased sensitivity to rewards, is observed in many psychiatric illnesses, particularly depression and anxiety disorders. Untreated anhedonia predicts worse clinical outcomes and poorer response to treatment, yet cognitive behavioral treatment approaches to target anhedonia are fraught with poor patient compliance in real-life settings. The proposed study aims to address this gap by 1) testing the usefulness of a non-invasive, computationally informed, cognitive training in boosting reward sensitivity and reducing anhedonia in depressed and anxious patients, and 2) delineating the neurocomputational mechanisms of change associated with such intervention. In other words, can we train the brain to obtain rewards and boost positive mood among depressed and anxious individuals? This project will help to develop a computational training protocol aimed at reducing anhedonia and improving existing interventions for psychiatric conditions characterized by reward processing deficits. Long-term goals include expanding this framework to a broader range of appetitive and social stimuli to develop precise cognitive training tools to treat anhedonia.

NCT ID: NCT05357547 Completed - Anhedonia Clinical Trials

Serotonin-receptor Agonism in Reward Processing

SARP
Start date: May 13, 2022
Phase: Phase 2
Study type: Interventional

There is growing animal and human evidence for role of 5HT1A receptor agonism in treating depression and reward deficits. The next step is to translate this evidence directly into humans by characterising the effects of buspirone, as a 5HT1A agonist, on cognitive models of reward and emotional processing. There is a paucity of behavioural evidence for the effect of 5HT1A receptor agonism, using buspirone as a probe, on primary reward processing (e.g. food), effort-based decision making or reward learning. Furthermore, the effects of 5HT1A agonism on non-emotive cognition, such as working memory, has yet to be investigated at a behavioural level in humans. This study will characterise the effects of buspirone, as a probe for 5HT1A receptor agonism, on reward processing in human cognitive models. Furthermore it will examine its role in emotional processing and working memory. This will add to the evidence base of the neurocognitive effects of 5HT1A receptor agonism in humans, which is of relevance to the development of this as a target for future treatment development. The study will be a double blinded, placebo controlled study involving healthy volunteers. Participants will receive a single dose of buspirone and then undergo a battery of psychometric testing to examine reward processing, emotional processing and a memory. Frequent monitoring of temperature and salivary cortisol shall be taken as surrogate markers of pre- and postsynaptic 5HT1A receptor activation.

NCT ID: NCT05306093 Completed - Anhedonia Clinical Trials

Depressed Mood and Anhedonia in Healthy Adults

MOOD5
Start date: January 7, 2022
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effect of nutraceutical supplement on depressed mood and anhedonia in volunteers after 8 weeks of consumption.

NCT ID: NCT05223842 Completed - Depression Clinical Trials

Family Promoting Positive Emotions Pilot Study

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Anhedonia is characterized by loss of interest or pleasure. The proposed pilot study would be the first to test an innovative, neuroscience-informed intervention in mothers reporting depressive symptoms and stress to enhance positive emotionality with the goal of preventing anhedonia and associated emotional disturbances in their children. This study will recruit dyads (mothers and their children) for the intervention.

NCT ID: NCT05165394 Completed - Clinical trials for Major Depressive Disorder

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

TERPSIS
Start date: November 30, 2021
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).

NCT ID: NCT05084924 Completed - Clinical trials for Major Depressive Disorder

Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia

DEBRA
Start date: November 2, 2021
Phase: N/A
Study type: Interventional

Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can increase goal-directed behavior in participants with major depressive disorder and elevated symptoms of anhedonia.

NCT ID: NCT04791137 Completed - Depression Clinical Trials

Feasibility Randomized Controlled Trial Using a 'Leapfrog' Design

Start date: April 9, 2021
Phase: N/A
Study type: Interventional

This study is a small-scale randomized controlled trial (RCT) using a 'Leapfrog' design (Blackwell, Woud, Margraf, & Schönbrodt, 2019) with the aim of investigating feasibility of this design in the context of an RCT of an internet-delivered intervention. The leapfrog design will be applied to a simple cognitive training intervention, imagery cognitive bias modification (imagery CBM), completed over a four-week training period. The trial will start with the three arms described in the initial registration, but these will be removed and new arms added over the course of the trial on the basis of sequential Bayesian analyses.

NCT ID: NCT04723147 Completed - Depression Clinical Trials

DTA (Dopaminergic Therapy for Anhedonia) Study

Start date: January 29, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this 6-week, double-blind, placebo-controlled, crossover study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Thirty-five male and female participants with depression, between the ages of 25-55 years of age, will be randomized to two study tracks (A and B) to receive both placebo and three doses of L-DOPA, given in different orders. Increases or decreases in each dose will occur gradually over 6 weeks of the study. Participants will complete lab tests, medical and psychiatric assessments, neurocognitive testing and functional MRI (fMRI) scans as part of the study. The total length of participation is about 2 months.

NCT ID: NCT04647019 Completed - Depression Clinical Trials

The Effects of Wild Blueberries on Depressive Symptoms in Young Adults

BluMood
Start date: November 26, 2021
Phase: N/A
Study type: Interventional

This study aims to investigate the effects of a 6-week dietary intervention of 22 g freeze-dried whole wild blueberry powder. The outcomes include measures of depression, anxiety, anhedonia, cognitive function, and biomarkers of inflammation and oxidative stress.